Huntington’s treatment helps Teva beat profit estimates as CEO eyes newer drug opportunities
By Steven Scheer JERUSALEM (Reuters) -Teva Pharmaceutical Industries on Wednesday reported higher-than-expected second-quarter profit, boosted by a sharp gain in sales of its Austedo treatment for Huntington’s disease that helped send its shares up as much as 14%. Chief Executive Richard Francis, who took the reins at the start of the year, is betting a…